Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine
Sleep · Sedation Complication
Primary: Difference in EEG Slow Wave Activity From Sham to In-phase Stimulation — 1.592; 1.694 Log(μV squared)
N/A N=100 Usability and Acceptability Study of the P-STEP Mobile Application
Asthma · Chronic Obstructive Pulmonary Disease · Interstitial Lung Disease
Primary: System Usability Scale — 57.92; 61.68 score on a scale
N/A N=10 One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Lung Cancer · Oligometastatic Lung Tumor
Primary: Feasibility of the ONE STOP Workflow as Measured by the Number of Participants With Successful Completion of the ONE STOP Workflow Through Treatment Delivery — 8…
Phase 2 N=157 Safety and Efficacy of BRM421 for Dry Eye Syndrome
Dry Eye Syndrome
Primary: Sign: Corneal Fluorescein Staining Score — -1.06; -1.16 score on a scale
N/A N=8 Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team
Common Infections · Urinary Tract Infections · Pneumonia
Primary: Days of Antibiotic Therapy Per 1000 Days of Care — 710; 744 Days of Antibiotic Therapy/1000 Bed Days
Phase 1 N=8 A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
Healthy Participants
Primary: The Maximum Observed Concentration of Nirmatrelvir in Breast Milk Over the Dosing Interval — 1904 Nanograms / milliliter (ng/mL)
N/A N=119 Exercise for Brain Health in the Fight Against Alzheimer's Disease
Healthy Cognition
Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5
N/A N=160 Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management
Opioid Use Disorder · Chronic Pain
Primary: Percent Participants Active in Medications for Opioid Use Disorder (MOUD) Treatment — 91.30; 86.30; 89.90; 83.20 Percent participants — p=0.43
N/A N=72 Esthetics of Dental Composite and Adhesive System
Cavities of Teeth
Primary: Patient Satisfaction of the Restoration's Appearance (Esthetics) Using the Visual Analog Scale — 85; 79 units on a scale
Phase 2 N=120 Addressing Heavy Alcohol Use Consumption With Kudzu
Alcohol Use Disorder · Sexually Transmitted Diseases
Primary: Number of Binge Drinking Days — 2.15; 2.15; 1.94; 2.21 number of days
Phase 1 N=15 PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
Colorectal Cancer · Colorectal Adenocarcinoma · Stage IVA Colorectal Cancer
Primary: Recurrence Rate at 1 Year — 6 Participants
N/A N=61 Mindfulness for Anger in Veterans With PTSD
Anger · Aggression
Primary: State Anger Scale — 27.34; 26.88; 23.47; 25.67 units on a scale — p=.14
Phase 3 N=666 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population — 5.55; 5.55 Months — p=0.502
N/A N=1,143 Revolutionizing Normative Re-education
College Drinking · Underage Drinking · Alcohol Use Disorder
Primary: Change From Baseline Daily Drinking at 4 Months — 2.11; 1.79; 2.18 Drinks per week — p=.155